Literature DB >> 1526873

High dose rate intracavitary brachytherapy for carcinoma of the cervix: the Madison system: I. Clinical and radiobiological considerations.

J A Stitt1, J F Fowler, B R Thomadsen, D A Buchler, B P Paliwal, T J Kinsella.   

Abstract

The decision to use five high dose rate intracavitary (HDR-ICR) insertions at weekly intervals for invasive carcinoma of the cervix treated at the University of Wisconsin Comprehensive Cancer Center (UWCCC) was made clinically. It was based on practical considerations and on previous clinical experience worldwide which showed that between 2 and 16 insertions have been used with apparently acceptable results. Although radiobiological considerations favor a large number of small doses, such a large number of HDR-ICR insertions is not clinically practical. Our strategy was to keep the biological effects of external beam and intracavitary insertions in the same ratio as used on a large series of patients treated here with low dose rate (LDR) therapy. This means keeping the same external beam treatment scheme and finding high dose rate (HDR) doses that are biologically equivalent to the previous LDR therapy, as far as possible. External beam and HDR intracavitary dose schedules for the Madison System of treating cervical carcinoma are described in detail. Because there is more repairable damage in late-reacting normal tissues, there is a bigger loss of sparing in these tissues than in tumors when changing from LDR to HDR, so total doses should be reduced more for equal late complications than for equal tumor control. The clinical decision was made to aim at equal tumor control. The possible increase in late complications has to be avoided by reducing the doses to critical normal tissues using extremely careful anatomic positioning of the HDR sources. Critical normal tissues must be kept further away from the radiation sources so that their doses are about 20% lower than with LDR geometry. This requires an extra separation of some millimeters depending on the anatomy and geometry of the individual insertion. The strategy is that the unfavourable radiobiological effects of a few large fractions must be counteracted by better physical dose distributions with HDR-ICR than with the previous LDR insertions. These good distributions are obtainable with the short exposures at HDR.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1526873     DOI: 10.1016/0360-3016(92)90690-j

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis.

Authors:  Vinai Gondi; Søren M Bentzen; Kathryn L Sklenar; Emily F Dunn; Daniel G Petereit; Scott P Tannehill; Margaret Straub; Kristin A Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-14       Impact factor: 7.038

Review 2.  Partial breast irradiation versus whole breast radiotherapy for early breast cancer.

Authors:  Brigid E Hickey; Margot Lehman
Journal:  Cochrane Database Syst Rev       Date:  2021-08-30

Review 3.  Partial breast irradiation for early breast cancer.

Authors:  Brigid E Hickey; Margot Lehman; Daniel P Francis; Adrienne M See
Journal:  Cochrane Database Syst Rev       Date:  2016-07-18

4.  Radiobiological equivalent of low/high dose rate brachytherapy and evaluation of tumor and normal responses to the dose.

Authors:  S Manimaran
Journal:  Radiat Med       Date:  2007-06-27

5.  Study of positional dependence of dose to bladder, pelvic wall and rectal points in High-Dose-Rate Brachytherapy in cervical cancer patients.

Authors:  Anil Kumar Talluri; Krishnam Raju Alluri; Deleep Kumar Gudipudi; Shabbir Ahamed; Madhusudhana M Sresty; Aparna Yarrama Reddy
Journal:  J Med Phys       Date:  2013-10

6.  Anatomic variation of prescription points and treatment volume with fractionated high-dose rate gynecological brachytherapy.

Authors:  Osman A Elhanafy; Rupak K Das; Bhudatt R Paliwal; Mostafa D Migahed; Hanim A Sakr; Mostafa Elleithy
Journal:  J Appl Clin Med Phys       Date:  2002       Impact factor: 2.102

7.  Interobserver variation in rectal and bladder doses in orthogonal film-based treatment planning of cancer of the uterine cervix.

Authors:  P Raghukumar; K Raghu Ram Nair; B Saju; G Zhenia; K T Divya; V S Shaiju; V Padmanabhan
Journal:  J Med Phys       Date:  2008-10

8.  A prospective randomized study on two dose fractionation regimens of high-dose-rate brachytherapy for carcinoma of the uterine cervix: comparison of efficacies and toxicities between two regimens.

Authors:  Taek Keun Nam; Sung Ja Ahn
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

Review 9.  Fraction size in radiation therapy for breast conservation in early breast cancer.

Authors:  Brigid E Hickey; Melissa L James; Margot Lehman; Phil N Hider; Mark Jeffery; Daniel P Francis; Adrienne M See
Journal:  Cochrane Database Syst Rev       Date:  2016-07-18

10.  Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy - a meta-analysis of clinical trials.

Authors:  Gustavo A Viani; Gustavo B Manta; Eduardo J Stefano; Ligia I de Fendi
Journal:  J Exp Clin Cancer Res       Date:  2009-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.